News | Focused Ultrasound Therapy | August 22, 2017

Insightec Announces Expanded Reach of MR-Guided Focused Ultrasound

More than 1,000 patients treated with Exablate Neuro system

Insightec Announces Expanded Reach of MR-Guided Focused Ultrasound

August 22, 2017 — Insightec announced recently that worldwide adoption of magnetic resonance (MR)-guided focused ultrasound continues to gain momentum as Exablate Neuro patient treatment numbers surpass the 1,000 mark. Medical facilities are ramping up their MR-guided focused ultrasound service and essential tremor patients are now being treated on a weekly basis at many sites, according to the company.

Exablate Neuro delivers focused ultrasound beams without any surgical incision to ablate the Vim of the thalamus, the tiny area of the brain thought to be responsible for causing tremors.

Regulatory approvals in the United States, Canada, Japan, Europe, Israel and Korea contributed to the accelerated adoption of focused ultrasound treatments worldwide. One year ago, on July 11, 2016, the U.S. Food and Drug Administration (FDA) approved Exablate Neuro as the first focused ultrasound device to treat essential tremor in patients who have not responded to medication.

“Having this newly established treatment at Weill Cornell Medical Center allows us to offer a safe and effective, incisionless treatment for patients with disabling tremor,” said M. Kaplitt, M.D., Ph.D., neurosurgeon at Weill Cornell Medical Center.

Essential tremor is a very common neurological condition that causes shaking of the hands, as well as other parts of the body. For most people, the severity of the tremor increases over time to the point where performing everyday tasks is impossible. This can have a significant impact on a person’s quality of life. If medications fail to control symptoms, it may also be treated with radiation or invasive surgical procedures, including traditional thalamotomy or deep brain stimulation.

Focused ultrasound is an incision-less treatment option that minimizes risk of complications such as infection and bleeding, reduces time spent recovering and rapidly returns patients to their lives.

“This past year, since having the focused ultrasound treatment, has simply been life-changing for me and my entire family”, commented Gregg Ley. Ley was treated one year ago at Swedish Medical Center in Seattle, Washington during the FDA pivotal study designed to evaluate the safety and efficacy of Exablate Neuro for the treatment of essential tremor in subjects for whom medications were not effective.

Over 30 Exablate Neuro systems are now actively treating patients for essential tremor as well as various research protocols for additional indications in 10 countries.

For more information: www.insightec.com

Related Content

Radiology, radiation therapy, PACS, Enterprise image, X-ray, DR Systems, CT, MRI, contrast, ultrasound, VNA, product comparisons, comparison charts on ITN magazine.
Feature | February 17, 2021
Imaging Technology News (ITN) maintains more than 40
Insightec plans to expand in Latin America through a partnership with Strattner
News | Focused Ultrasound Therapy | February 16, 2021
February 16, 2021 — Insightec, a global healthcare company focused on creating the next generation of patient care, a
Immunotherapy-based precision medicine clinical trials being developed

Getty Images

News | Prostate Cancer | February 16, 2021
February 16, 2021 — Black men die more often of prostate cancer yet, paradoxically, have greater survival benefits fr
Real Time Imaging Technologies LLC iannounced that it has received U.S. Patent No. 10,898,070 IMAGING APPARATUS AND METHODS which covers the company’s methods for incorporating microlens into X-ray imaging detectors that enables significantly lower radiation dose without compromising image resolution.

Getty Images

News | Radiation Dose Management | February 05, 2021
February 5, 2021 — 

Images in 69-year-old man with biopsy-confirmed Gleason score 7 (3+4) prostate cancer. (a) Pretreatment axial T2-weighted fast spin-echo MRI scan (repetition time msec/echo time msec, 3820/97) shows tumor in midline anterior transition zone (arrow). (b) Intraoperative MRI scan shows contoured rectal wall (red line), prostate margin (blue outline), and region of interest (orange outline). Because the urethra was included in planned treatment volume, a suprapubic catheter was placed for continuous bladder drainage during treatment. (c) Intraoperative MRI scan shows focused ultrasound beam path (blue) overlaid on treatment plan. Rectangles illustrate each sonication spot. (d) Thermal map image obtained during treatment with heat deposition color coded in red overlaid on sonication spot. (e) Axial gadopentetate dimeglumine-enhanced MRI scan (230/2.97) obtained immediately after treatment shows devascularized ablated volume (arrows). (f) Corresponding T2-weighted fast spin-echo MRI scan (3820/97) at 5 months after ablation shows complete involution of transition zone. All seven cores from treatment area margins were negative for cancer at biopsy. Image courtesy of the Radiological Society of North America

News | Prostate Cancer | February 05, 2021
February 5, 2021 — A technique that delivers...
Ludwig Chicago Co-director Ralph Weichselbaum and Kaiting Yang, a postdoctoral researcher in Weichselbaum's lab.

Ludwig Chicago Co-director Ralph Weichselbaum and Kaiting Yang, a postdoctoral researcher in Weichselbaum's lab. Image courtesy of Ludwig Cancer Research

News | Radiation Therapy | January 28, 2021
January 28, 2021 — A study led by Ludwig Chicago